An update: current and prospective treatments for adult-onset Still’s disease

References

• Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70:118–136.
   Google Scholar
• Arlet JB, Le TH, Marinho A, et al. Reactive haemophagocytic syndrome in adult-onset Still’s disease: a report of six patients and a review of the literature. Ann Rheum Dis. 2006;65:1596–1601.
   Google Scholar
• Bae CB, Jung JY, Kim HA, et al. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features, predictive factors, and prognosis in 21 patients. Medicine (Baltimore). 2015;94:e451.
   Google Scholar
• Jamilloux Y, Gerfaud-Valentin M, Martinon F, et al. Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart. Immunol Res. 2015;61:53–62.
   Google Scholar
• Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol. 2008;22:773–792.
   Google Scholar
• Wouters JM, Reekers P, van de Putte LB. Adult-onset Still’s disease. Disease course and HLA associations. Arthritis Rheum. 1986;29:415–418.
   Google Scholar
• Wouters JM, van der Veen J, van de Putte LB, et al. Adult onset Still’s disease and viral infections. Ann Rheum Dis. 1988;47:764–767.
   Google Scholar
• Fujita M, Hatachi S, Yagita M. Acute Chlamydia pneumoniae infection in the pathogenesis of autoimmune diseases. Lupus. 2009;18:164–168.
   Google Scholar
• Pouchot J, Ouakil H, Debin ML, et al. Adult Still’s disease associated with acute human parvovirus B19 infection. Lancet. 1993;341:1280–1281.
   Google Scholar
• Chen DY, Lan JL, Lin FJ, et al. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol. 2004;31:2189–2198.
   Google Scholar
• Choi JH, Suh CH, Lee YM, et al. Serum cytokine profiles in patients with adult onset Still’s disease. J Rheumatol. 2003;30:2422–2427.
   Google Scholar
• Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–430.
   Google Scholar
• Chen DY, Lan JL, Lin FJ, et al. Association of intercellular adhesion molecule-1 with clinical manifestations and interleukin-18 in patients with active, untreated adult-onset Still’s disease. Arthritis Rheum. 2005;53:320–327.
   Google Scholar
• Kim HA, An JM, Nam JY, et al. Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still’s disease. J Rheumatol. 2012;39:1399–1406.
   Google Scholar
• Jung SY, Park YB, Ha YJ, et al. Serum calprotectin as a marker for disease activity and severity in adult-onset Still’s disease. J Rheumatol. 2010;37:1029–1034.
   Google Scholar
• Bae CB, Suh CH, An JM, et al. Serum S100A12 may be a useful biomarker of disease activity in adult-onset Still’s disease. J Rheumatol. 2014;41:2403–2408.
   Google Scholar
• Zou YQ, Lu LJ, Li SJ, et al. The levels of macrophage migration inhibitory factor as an indicator of disease activity and severity in adult-onset Still’s disease. Clin Biochem. 2008;41:519–524.
   Google Scholar
• Kwok JS, Wong PC, Luk MC, et al. Use of glycosylated ferritin assay to aid the diagnosis of adult-onset Still’s disease: a local laboratory experience in Hong Kong. Rheumatol Int. 2012;32:2583–2584.
   Google Scholar
• Kim HA, Choi B, Suh CH, et al. Highly expression of CD11b and CD32 on peripheral blood mononuclear cells from patients with adult-onset still’s disease. Int J Mol Sci. 2017;18. pii: E202. doi: 10.3390/ijms18010202.
   Google Scholar
• Chen DY, Chuang HC, Lan JL, et al. Germinal center kinase-like kinase (GLK/MAP4K3) expression is increased in adult-onset Still’s disease and may act as an activity marker. BMC Med. 2012;10:84.
   Google Scholar
• Komiya A, Matsui T, Nogi S, et al. Neutrophil CD64 is upregulated in patients with active adult-onset Still’s disease. Scand J Rheumatol. 2012;41:156–158.
   Google Scholar
• Ohta A, Yamaguchi M, Kaneoka H, et al. Adult Still’s disease: review of 228 cases from the literature. J Rheumatol. 1987;14:1139–1146.
   Google Scholar
• Iliou C, Papagoras C, Tsifetaki N, et al. Adult-onset Still’s disease: clinical, serological and therapeutic considerations. Clin Exp Rheumatol. 2013;31:47–52.
   Google Scholar
• Franchini S, Dagna L, Salvo F, et al. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still’s disease. Arthritis Rheum. 2010;62:2530–2535.
   Google Scholar
• Kim HA, Sung JM, Suh CH. Therapeutic responses and prognosis in adult-onset Still’s disease. Rheumatol Int. 2012;32:1291–1298.
   Google Scholar
• Gerfaud-Valentin M, Maucort-Boulch D, Hot A, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93:91–99.
   Google Scholar
• Castañeda S, Blanco R, González-Gay MA. Adult-onset Still’s disease: advances in the treatment. Best Pract Res Clin Rheumatol. 2016;30:222–238.
   Google Scholar
• Kong XD, Xu D, Zhang W, et al. Clinical features and prognosis in adult-onset Still’s disease: a study of 104 cases. Clin Rheumatol. 2010;29:1015–1019.
   Google Scholar
• Iglesias J, Sathiraju S, Marik PE. Severe systemic inflammatory response syndrome with shock and ARDS resulting from Still’s disease: clinical response with high-dose pulse methylprednisolone therapy. Chest. 1999;115:1738–1740.
   Google Scholar
• Khraishi M, Fam AG. Treatment of fulminant adult Still’s disease with intravenous pulse methylprednisolone therapy. J Rheumatol. 1991;18:1088–1090.
   Google Scholar
• Zhang Y, Yang Y, Bai Y, et al. Clinical characteristics and follow-up analysis of adult-onset Still’s disease complicated by hemophagocytic lymphohistiocytosis. Clin Rheumatol. 2016;35:1145–1151.
   Google Scholar
• Valluru N, Tammana VS, Windham M, et al. Rare manifestation of a rare disease, acute liver failure in adult onset Still’s disease: dramatic response to methylprednisolone pulse therapy-a case report and review. Case Rep Med. 2014;2014:375035.
   Google Scholar
• Fautrel B, Borget C, Rozenberg S, et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still’s disease. J Rheumatol. 1999;26:373–378.
   Google Scholar
• Aydintug AO, D’Cruz D, Cervera R, et al. Low dose methotrexate treatment in adult Still’s disease. J Rheumatol. 1992;19:431–435.
   Google Scholar
• Kontzias A, Efthimiou P. Adult-onset Still’s disease: pathogenesis, clinical manifestations and therapeutic advances. Drugs. 2008;68:319–337.
   Google Scholar
• Nakamura H, Odani T, Shimizu Y, et al. Usefulness of tacrolimus for refractory adult-onset still’s disease: report of six cases. Mod Rheumatol. 2016;26:963–967.
   Google Scholar
• Cefle A. Leflunomide and azathioprine combination in refractory adult-onset Still’s disease. Ann Pharmacother. 2005;39:764–767.
   Google Scholar
• Hot A, Toh ML, Coppéré B, et al. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a case-control study of 8 patients. Medicine (Baltimore). 2010;89:37–46.
   Google Scholar
• Tsuji Y, Iwanaga N, Adachi A, et al. Successful treatment with intravenous cyclophosphamide for refractory adult-onset Still’s disease. Case Rep Rheumatol. 2015;2015:163952.
   Google Scholar
• Hoffman HM. Therapy of autoinflammatory syndromes. J Allergy Clin Immunol. 2009;124:1129–1138.
   Google Scholar
• Hong D, Yang Z, Han S, et al. Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety. Drug Des Devel Ther. 2014;8:2345–2357.
   Google Scholar
• Sfriso P, Priori R, Valesini G, et al. Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol. 2016;35:1683–1689.
   Google Scholar
• Giampietro C, Ridene M, Lequerre T, et al. Anakinra in adult-onset Still’s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken). 2013;65:822–826.
   Google Scholar
• Loh NK, Lucas M, Fernandez S, et al. Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra. Int Med J. 2012;42:1358–1362.
   Google Scholar
• Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J. Refractory adult onset Still’s disease successfully treated with anakinra. Ann Rheum Dis. 2005;64:647–648.
   Google Scholar
• Fitzgerald AA, Leclercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum. 2005;52:1794–1803.
   Google Scholar
• Kalliolias GD, Georgiou PE, Antonopoulos IA, et al. Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis. 2007;66:842–843.
   Google Scholar
• Kötter I, Wacker A, Koch S, et al. Anakinra in patients with treatment-resistant adult-onset Still’s disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum. 2007;37:189–197.
   Google Scholar
• Lequerré T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67:302–308.
   Google Scholar
• Nordström D, Knight A, Luukkainen R, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still’s disease. An open, randomized, multicenter study. J Rheumatol. 2012;39:2008–2011.
   Google Scholar
• Ortiz-Sanjuan F, Blanco R, Riancho-Zarrabeitia L, et al. Efficacy of anakinra in refractory adult-onset Still’s disease: multicenter study of 41 patients and literature review. Medicine (Baltimore). 2015;94:e1554.
   Google Scholar
• Luconi N, Risse J, Busato T, et al. Myocarditis in a young man with adult onset Still’s disease successfully treated with Il-1 blocker. Int J Cardiol. 2015;189:220–222.
   Google Scholar
• Mylona E, Golfinopoulou S, Samarkos M, et al. Acute hepatitis in adult Still’s disease during corticosteroid treatment successfully treated with anakinra. Clin Rheumatol. 2008;27:659–661.
   Google Scholar
• Taylor SA, Vittorio JM, Martinez M, et al. Anakinra-induced acute liver failure in an adolescent patient with Still’s disease. Pharmacotherapy. 2016;36:e1–e4.
   Google Scholar
• Guignard S, Dien G, Dougados M. Severe systemic inflammatory response syndrome in a patient with adult onset Still’s disease treated with the anti-IL1 drug anakinra: a case report. Clin Exp Rheumatol. 2007;25:758–759.
   Google Scholar
• Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. 2015;10:19.
   Google Scholar
• Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416–2425.
   Google Scholar
• Kontzias A, Efthimiou P. The use of canakinumab, a novel IL-1beta long-acting inhibitor, in refractory adult-onset Still’s disease. Semin Arthritis Rheum. 2012;42:201–205.
   Google Scholar
• Barsotti S, Neri R, Iacopetti V, et al. Successful treatment of refractory adult-onset still disease with canakinumab: a case report. J Clin Rheumatol. 2014;20:121.
   Google Scholar
• Lo Gullo A, Caruso A, Pipitone N, et al. Canakinumab in a case of adult onset still’s disease: efficacy only on systemic manifestations. Joint Bone Spine. 2014;81:376–377.
   Google Scholar
• Banse C, Vittecoq O, Benhamou Y, et al. Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still’s disease. Joint Bone Spine. 2013;80:653–655.
   Google Scholar
• Dubois EA, Rissmann R, Cohen AF. Rilonacept and canakinumab. Br J Clin Pharmacol. 2011;71:639–641.
   Google Scholar
• Petryna O, Cush JJ, Efthimiou P. IL-1 trap rilonacept in refractory adult onset Still’s disease. Ann Rheum Dis. 2012;71:2056–2057.
   Google Scholar
• Cavagna L, Caporali R, Epis O, et al. Infliximab in the treatment of adult Still’s disease refractory to conventional therapy. Clin Exp Rheumatol. 2001;19:329–332.
   Google Scholar
• Kraetsch HG, Antoni C, Kalden JR, et al. Successful treatment of a small cohort of patients with adult onset of Still’s disease with infliximab: first experiences. Ann Rheum Dis. 2001;60(Suppl 3):iii55–iii57.
   Google Scholar
• Fautrel B, Sibilia J, Mariette X, et al. Tumour necrosis factor alpha blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64:262–266.
   Google Scholar
• Fujii K, Rokutanda R, Osugi Y, et al. Adult-onset Still’s disease complicated by autoimmune hepatitis: successful treatment with infliximab. Int Med. 2012;51:1125–1128.
   Google Scholar
• Singh B, Biboa J, Musuku S, et al. Reversal of severe hepatitis with infliximab in adult-onset Still’s disease. Am J Med. 2013;126:e3–e4.
   Google Scholar
• Husni ME, Maier AL, Mease PJ, et al. Etanercept in the treatment of adult patients with Still’s disease. Arthritis Rheum. 2002;46:1171–1176.
   Google Scholar
• Benucci M, Li GF, Del Rosso A, et al. Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still’s disease: the first case report. Clin Exp Rheumatol. 2005;23:733.
   Google Scholar
• Lee WS, Yoo SH, Ko RE, et al. Adalimumab in the treatment of refractory adult-onset Still’s disease. Int J Rheum Dis. 2014 Jun 21. doi: 10.1111/1756-185X.12421. [Epub ahead of print].
   Google Scholar
• Mehta BM, Hashkes PJ, Avery R, et al. A 21-year-old man with Still’s disease with fever, rash, and pancytopenia. Arthritis Care Res (Hoboken). 2010;62:575–579.
   Google Scholar
• Agarwal S, Moodley J, Ajani Goel G, et al. A rare trigger for macrophage activation syndrome. Rheumatol Int. 2011;31:405–407.
   Google Scholar
• Nakahara H, Mima T, Yoshio-Hoshino N, et al. A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol. 2009;19:69–72.
   Google Scholar
• De Bandt M, Saint-Marcoux B. Tocilizumab for multirefractory adult-onset Still’s disease. Ann Rheum Dis. 2009;68:153–154.
   Google Scholar
• Matsumoto K, Nagashima T, Takatori S, et al. Glucocorticoid and cyclosporine refractory adult onset Still’s disease successfully treated with tocilizumab. Clin Rheumatol. 2009;28:485–487.
   Google Scholar
• Rech J, Ronneberger M, Englbrecht M, et al. Successful treatment of adult-onset Still’s disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade. Ann Rheum Dis. 2011;70:390–392.
   Google Scholar
• Puechal X, DeBandt M, Berthelot JM, et al. Tocilizumab in refractory adult Still’s disease. Arthritis Care Res (Hoboken). 2011;63:155–159.
   Google Scholar
• Ortiz-Sanjuan F, Blanco R, Calvo-Rio V, et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still’s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol. 2014;66:1659–1665.
   Google Scholar
• Nishina N, Kaneko Y, Kameda H, et al. The effect of tocilizumab on preventing relapses in adult-onset Still’s disease: a retrospective, single-center study. Mod Rheumatol. 2015;25:401–404.
   Google Scholar
• Song ST, Kim JJ, Lee S, et al. Efficacy of tocilizumab therapy in Korean patients with adult-onset Still’s disease: a multicentre retrospective study of 22 cases. Clin Exp Rheumatol. 2016;34:S64–S71.
   Google Scholar
• Kobayashi M, Takahashi Y, Yamashita H, et al. Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011;21:92–96.
   Google Scholar
• Savage E, Wazir T, Drake M, et al. Fulminant myocarditis and macrophage activation syndrome secondary to adult-onset Still’s disease successfully treated with tocilizumab. Rheumatology (Oxford). 2014;53:1352–1353.
   Google Scholar
• Watanabe E, Sugawara H, Yamashita T, et al. Successful tocilizumab therapy for macrophage activation syndrome associated with adult-onset still’s disease: a case-based review. Case Rep Med. 2016;2016:5656320.
   Google Scholar
• Quartuccio L, Maset M, De Vita S. Efficacy of abatacept in a refractory case of adult-onset Still’s disease. Clin Exp Rheumatol. 2010;28:265–267.
   Google Scholar
• Ostrowski RA, Tehrani R, Kadanoff R. Refractory adult-onset still disease successfully treated with abatacept. J Clin Rheumatol. 2011;17:315–317.
   Google Scholar
• Belfeki N, Smiti Khanfir M, Said F, et al. Successful treatment of refractory adult onset Still’s disease with rituximab. Reumatismo. 2016;68:159–162.
   Google Scholar
• Ruiz de Souza V, Kaveri SV, Kazatchkine MD. Intravenous immunoglobulin (IVIg) in the treatment of autoimmune and inflammatory diseases. Clin Exp Rheumatol. 1993;11(Suppl 9):S33–S36.
   Google Scholar
• Kazatchkine MD, Bellon B, Kaveri SV. Mechanisms of action of intravenous immunoglobulin (IVIG). Mult Scler. 2000;6(Suppl 2):S24–S26; discussion S33.
   Google Scholar
• Liozon E, Ly K, Aubard Y, et al. Intravenous immunoglobulins for adult Still’s disease and pregnancy. Rheumatology (Oxford). 1999;38:1024–1025.
   Google Scholar
• Bennett AN, Peterson P, Sangle S, et al. Adult onset Still’s disease and collapsing glomerulopathy: successful treatment with intravenous immunoglobulins and mycophenolate mofetil. Rheumatology (Oxford). 2004;43:795–799.
   Google Scholar
• Chen DY, Chen YM, Lan JL, et al. Potential role of Th17 cells in the pathogenesis of adult-onset Still’s disease. Rheumatology (Oxford). 2010;49:2305–2312.
   Google Scholar